重新利用抗氧化和抗炎剂N-乙酰半胱氨酸来治疗新冠肺炎。
Repurposing the antioxidant and anti-inflammatory agent N-acetyl cysteine for treating COVID-19.
作者信息
Finsterer Josef, Scorza Fulvio A, Scorza Carla A, Fiorini Ana C
机构信息
Neurological Department, Messerli Institute, Vienna 1180, Austria.
Department of Neurology, University of Sao Paolo, Sao Paolo 01000-000, Brazil.
出版信息
World J Virol. 2022 Jan 25;11(1):82-84. doi: 10.5501/wjv.v11.i1.82.
Abstract
Although several considerations have been raised suggesting a beneficial effect of N-acetyl cysteine (NAC) for the treatment of severe acute respiratory syndrome coronavirus 2 infection, there is currently no clinical evidence that NAC truly prevents coronavirus disease 2019 (COVID-19), reduces the severity of the disease, or improves the outcome. Appropriately designed clinical trials are warranted to prove or disprove a therapeutic effect of NAC for COVID-19 patients.
摘要
尽管已经提出了一些考虑因素，表明N-乙酰半胱氨酸（NAC）对治疗严重急性呼吸综合征冠状病毒2感染有有益作用，但目前尚无临床证据表明NAC能真正预防2019冠状病毒病（COVID-19）、降低疾病严重程度或改善预后。有必要进行设计合理的临床试验，以证实或反驳NAC对COVID-19患者的治疗效果。
相似文献
1
Repurposing the antioxidant and anti-inflammatory agent N-acetyl cysteine for treating COVID-19.重新利用抗氧化和抗炎剂N-乙酰半胱氨酸来治疗新冠肺炎。
World J Virol. 2022 Jan 25;11(1):82-84. doi: 10.5501/wjv.v11.i1.82.
2
N-acetyl cysteine as a potential regulator of SARS-CoV-2-induced male reproductive disruptions.N-乙酰半胱氨酸作为严重急性呼吸综合征冠状病毒2（SARS-CoV-2）诱导的男性生殖功能障碍的潜在调节因子。
Middle East Fertil Soc J. 2022;27(1):14. doi: 10.1186/s43043-022-00104-8. Epub 2022 Jun 15.
3
N-acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia: a two-center retrospective cohort study.N-乙酰半胱氨酸降低 COVID-19 肺炎患者机械通气和死亡风险的：一项两中心回顾性队列研究。
Infect Dis (Lond). 2021 Nov;53(11):847-854. doi: 10.1080/23744235.2021.1945675. Epub 2021 Jun 29.
4
The effects of -acetyl cysteine on acute viral respiratory infections in humans: A rapid review.N-乙酰半胱氨酸对人类急性病毒性呼吸道感染的影响：快速综述。
Adv Integr Med. 2020 Dec;7(4):232-239. doi: 10.1016/j.aimed.2020.07.006. Epub 2020 Aug 3.
5
Pathogenesis-directed therapy of 2019 novel coronavirus disease.针对 2019 新型冠状病毒病的发病机制导向治疗。
J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10.
6
Human and novel coronavirus infections in children: a review.儿童人感染和新型冠状病毒感染：综述。
Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25.
7
Therapeutic potential of N-acetyl cysteine during COVID-19 epoch.新冠疫情期间N-乙酰半胱氨酸的治疗潜力
World J Virol. 2022 Mar 25;11(2):104-106. doi: 10.5501/wjv.v11.i2.104.
8
N-Acetylcysteine as Adjuvant Therapy for COVID-19 - A Perspective on the Current State of the Evidence.N-乙酰半胱氨酸作为新型冠状病毒肺炎的辅助治疗——证据现状透视
J Inflamm Res. 2021 Jul 6;14:2993-3013. doi: 10.2147/JIR.S306849. eCollection 2021.
9
Improved oxidative status in major abdominal surgery patients after N-acetyl cystein supplementation.补充N-乙酰半胱氨酸后，腹部大手术患者的氧化状态得到改善。
Nutr J. 2015 Jan 6;14:4. doi: 10.1186/1475-2891-14-4.
10
Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease.N-乙酰-L-半胱氨酸在慢性阻塞性肺疾病中的多效性作用。
Expert Rev Respir Med. 2018 Aug;12(8):693-708. doi: 10.1080/17476348.2018.1495562. Epub 2018 Jul 17.
引用本文的文献
1
Effect of N-Acetylcysteine on mortality in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials.N-乙酰半胱氨酸对COVID-19患者死亡率的影响：一项随机对照试验的系统评价和荟萃分析
Inflammopharmacology. 2025 Aug;33(8):4871-4877. doi: 10.1007/s10787-025-01876-x. Epub 2025 Jul 29.
2
The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications.缺血再灌注损伤在类风湿性关节炎、长新冠和 ME/CFS 等慢性、复发性疾病中的潜在作用：证据、机制和治疗意义。
Biochem J. 2022 Aug 31;479(16):1653-1708. doi: 10.1042/BCJ20220154.
本文引用的文献
1
Therapeutic potential of N-acetyl cysteine (NAC) in preventing cytokine storm in COVID-19: review of current evidence.N-乙酰半胱氨酸 (NAC) 在预防 COVID-19 细胞因子风暴中的治疗潜力：当前证据综述。
Eur Rev Med Pharmacol Sci. 2021 Mar;25(6):2802-2807. doi: 10.26355/eurrev_202103_25442.
2
Bottom-up analysis of emergent properties of N-acetylcysteine as an adjuvant therapy for COVID-19.对N-乙酰半胱氨酸作为COVID-19辅助治疗药物的涌现特性进行自下而上的分析。
World J Virol. 2021 Mar 25;10(2):34-52. doi: 10.5501/wjv.v10.i2.34.
3
Immune Competence and Minimizing Susceptibility to COVID-19 and Other Immune System Threats.免疫能力与降低对新冠病毒及其他免疫系统威胁的易感性
Altern Ther Health Med. 2020 Aug;26(S2):94-99.
4
Direct Clinical Evidence Recommending the Use of Proteinase K or Dithiothreitol to Pretreat Sputum for Detection of SARS-CoV-2.推荐使用蛋白酶K或二硫苏糖醇预处理痰液以检测新型冠状病毒2的直接临床证据。
Front Med (Lausanne). 2020 Sep 18;7:549860. doi: 10.3389/fmed.2020.549860. eCollection 2020.
5
Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19.使用 N-乙酰半胱氨酸预防和辅助治疗 COVID-19 的理由。
FASEB J. 2020 Oct;34(10):13185-13193. doi: 10.1096/fj.202001807. Epub 2020 Aug 11.
6
N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2.N-乙酰半胱氨酸：一种治疗 SARS-CoV-2 的潜在药物。
Med Hypotheses. 2020 Oct;143:109862. doi: 10.1016/j.mehy.2020.109862. Epub 2020 May 30.
7
N-acetylcysteine modulates lipopolysaccharide-induced intestinal dysfunction.N-乙酰半胱氨酸调节脂多糖诱导的肠道功能障碍。
Sci Rep. 2019 Jan 30;9(1):1004. doi: 10.1038/s41598-018-37296-x.
8
N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner.N-乙酰半胱氨酸通过依赖 Akt 的方式下调 Foxo1 来保护抗黑色素瘤细胞毒性 T 细胞免于因快速扩增而衰竭。
Cancer Immunol Immunother. 2018 Apr;67(4):691-702. doi: 10.1007/s00262-018-2120-5. Epub 2018 Feb 2.
9
The anti-inflammatory effects of acetaminophen and N-acetylcysteine through suppression of the NLRP3 inflammasome pathway in LPS-challenged piglet mononuclear phagocytes.对乙酰氨基酚和N-乙酰半胱氨酸通过抑制脂多糖刺激的仔猪单核吞噬细胞中NLRP3炎性小体途径发挥的抗炎作用。
Innate Immun. 2015 Aug;21(6):587-97. doi: 10.1177/1753425914566205. Epub 2015 Jan 8.
10
Interaction of N-acetylcysteine and cysteine in human plasma.N-乙酰半胱氨酸和半胱氨酸在人血浆中的相互作用。
J Pharm Sci. 2012 Dec;101(12):4653-9. doi: 10.1002/jps.23325. Epub 2012 Sep 27.
Zotero 插件